Acute promyelocytic leukemia witht(15;17) abnormality after chemotherapy containing etoposide for langerhans cell histiocytosis
1993; Wiley; Volume: 72; Issue: 12 Linguagem: Inglês
10.1002/1097-0142(19931215)72
ISSN1097-0142
AutoresKeizo Horibe, Takeji Matsushita, Shin‐ichiro Numata, Yuji Miyajima, Isao Katayama, Taeru Kitabayashi, Mari Yanai, Noriko Sekiguchi, Shinzo Egi,
Tópico(s)Multiple Myeloma Research and Treatments
ResumoCancerVolume 72, Issue 12 p. 3723-3726 ArticleFree Access Acute promyelocytic leukemia with t(15;17) abnormality after chemotherapy containing etoposide for langerhans cell histiocytosis Keizo Horibe M.D., Corresponding Author Keizo Horibe M.D. Department of Pediatrics, Nagoya University School of Medicine, Nagoya, JapanDepartment of Pediatrics, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466, Japan===Search for more papers by this authorTakeji Matsushita M.D., Takeji Matsushita M.D. Department of Pediatrics, National Medical Center, Tokyo, JapanSearch for more papers by this authorShin-Ichiro Numata M.D., Shin-Ichiro Numata M.D. Department of Pediatrics, Nagoya University School of Medicine, Nagoya, JapanSearch for more papers by this authorYuji Miyajima M.D., Yuji Miyajima M.D. Department of Pediatrics, Nagoya University School of Medicine, Nagoya, JapanSearch for more papers by this authorIsao Katayama M.D., Isao Katayama M.D. Department of Pediatrics, Nagoya University School of Medicine, Nagoya, JapanSearch for more papers by this authorTaeru Kitabayashi M.D., Taeru Kitabayashi M.D. Department of Pediatrics, National Medical Center, Tokyo, JapanSearch for more papers by this authorMari Yanai M.D., Mari Yanai M.D. Department of Pediatrics, National Medical Center, Tokyo, JapanSearch for more papers by this authorNoriko Sekiguchi M.D., Noriko Sekiguchi M.D. Department of Pediatrics, National Medical Center, Tokyo, JapanSearch for more papers by this authorShinzo Egi M.D., Shinzo Egi M.D. Department of Pediatrics, National Medical Center, Tokyo, JapanSearch for more papers by this author Keizo Horibe M.D., Corresponding Author Keizo Horibe M.D. Department of Pediatrics, Nagoya University School of Medicine, Nagoya, JapanDepartment of Pediatrics, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466, Japan===Search for more papers by this authorTakeji Matsushita M.D., Takeji Matsushita M.D. Department of Pediatrics, National Medical Center, Tokyo, JapanSearch for more papers by this authorShin-Ichiro Numata M.D., Shin-Ichiro Numata M.D. Department of Pediatrics, Nagoya University School of Medicine, Nagoya, JapanSearch for more papers by this authorYuji Miyajima M.D., Yuji Miyajima M.D. Department of Pediatrics, Nagoya University School of Medicine, Nagoya, JapanSearch for more papers by this authorIsao Katayama M.D., Isao Katayama M.D. Department of Pediatrics, Nagoya University School of Medicine, Nagoya, JapanSearch for more papers by this authorTaeru Kitabayashi M.D., Taeru Kitabayashi M.D. Department of Pediatrics, National Medical Center, Tokyo, JapanSearch for more papers by this authorMari Yanai M.D., Mari Yanai M.D. Department of Pediatrics, National Medical Center, Tokyo, JapanSearch for more papers by this authorNoriko Sekiguchi M.D., Noriko Sekiguchi M.D. Department of Pediatrics, National Medical Center, Tokyo, JapanSearch for more papers by this authorShinzo Egi M.D., Shinzo Egi M.D. Department of Pediatrics, National Medical Center, Tokyo, JapanSearch for more papers by this author First published: 15 December 1993 https://doi.org/10.1002/1097-0142(19931215)72:12 3.0.CO;2-YCitations: 34AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract Background. Epipodophyllotoxins, etoposide and teniposide, have been shown to be implicated in the development of acute myelogenous leukemia in patients treated for solid tumors or acute lymphoblastic leukemia. Etoposide has been shown to be an effective agent against Langerhans cell histiocytosis (LCH) and has gained wider use recently for first-line and salvage chemotherapy in cases of systemic LCH. Methods. The authors report two patients with secondary acute promyelocytic leukemia (APL) with a t(15;17) abnormality after chemotherapy that included etoposide for the treatment of LCH. Results. Patient 1, a 6-year-old girl, had APL develop 11 months after cessation of therapy that included vinblastine, prednisolone, and etoposide (9600 mg/m2 in total dose) for LCH. Patient 2, a 3-year-old girl, had APL develop 9 months after cessation of therapy that included vincristine, methotrexate, prednisolone, cyclophosphamide (10,800 mg/m2), and etoposide (4800 mg/ m2) for LCH. Conclusions. The authors have experience with four patients treated with etoposide for LCH and suggest that there is a predisposition to secondary APL with t(15;17) for patients with LCH treated with etoposide. The authors warn against the imprudent use of etoposide as a first-line therapy for LCH. References 1 Meadows AT, Baum E, Fossati-Bellani F, Green D, Jenkin RDT, Marsden B, et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol 1985; 3: 532– 8. 2 Tucker MA, Meadows AT, Boice JD, Stovall M, Oberlin O, Stone BJ, et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987; 78: 459– 64. 3 Ratain MJ, Kaminer LS, Bitran JD, Larson RA, Le Beau MM, Skosey C, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 1987; 70: 1412– 7. 4 Pui CH, Behm FG, Raimondi SC, Dodge RK, George SL, Rivera GK, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 1989; 321: 136– 42. 5 DeVore R, Whitlock J, Hainsworth JD, Johnson DH. Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q. Ann Intern Med 1989; 110: 740– 2. 6 McClain KL. Histiocytic proliferative diseases. In: DJ Fernbach, TJ Vietti, editors. Clinical pediatric oncology. St. Louis: CV Mosby, 1991: 397– 408. 7 Hocking WG, Swanson M. Multifocal eosinophilic granuloma. Cancer 1986: 58: 840– 2. 8 Broadbent V, Pritchart J, Yeomans E. Etoposide (VP 16) in the treatment of multisystem Langerhans cell histiocytosis(histiocytosis X). Med Pediatr Oncol 1989; 17: 97– 100. 9 Creutzig U, Ritter J, Schellong G. Acute myelogenous leukemia in childhood. Berlin: Springer-Verlag, 1990. 10 Komp DM. Long-term sequelae of histiocytosis X. Am J Pediatr Hematol Oncol 1981; 3: 165– 8. 11 Greenberger JS, Crocker AC, Vawter G, Jaffe N, Cassady JR. Results of treatment of 127 patients with systemic histiocytosis (Letterer-Siwe syndrome, Schuller-Christian syndrome and multifocal eosinophilic granuloma). Medicine 1981; 60: 311– 37. 12 Gushiken T, Hirayama K. A case report of acute myeloblastic leukemia after treatment of Langerhans cell histiocytosis [in Japanese]. Jpn J Pediatr 1992; 45: 609– 12. 13 Ise T. Second malignant neoplasms in children [in Japanese]. Jpn J Cancer Chemother 1986; 13: 1514– 22. 14 Whitlock JA, Green JP, Lukens JN. Epipodophyllotoxin-related leukemia. Cancer 1991; 68: 600– 4. 15 Maraschin J, Dutrillaux B, Aurias A. Chromosome aberrations induced by etoposide (VP-16) are not random. Int J Cancer 1990; 46: 808– 12. 16 Detourmignies L, Castaigne S, Stoppa AM, Harousseau JL, Sadoun A, Janvier M, et al. Therapy-related acute promyelocytic leukemia: a report on 16 cases. J Clin Oncol 1992; 10: 1430– 5. 17 Fenaux P, Lucidarme D, Lai JL, Bauters F. Favorable cytogenetic abnormalities in secondary leukemia. Cancer 1989; 63: 2505– 8. 18 Whang-Peng J, Young RC, Lee EC, Longo DL, Schechter GP, DeVita VT. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 1988; 71: 403– 14. 19 Kantarjian HM, Keating MJ, Walters RS, Beran M, McLaughlin P, McCredie KB, et al. The association of specific "favorable" cytogenetic abnormalities with secondary leukemia. Cancer 1986; 58: 924– 7. 20 Hansen MF, Koufos A, Gallie BL, Phillips RA, Fodstad O, Brogger A, et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci USA 1985; 82: 6216– 20. 21 Greene MH, Boice JD Jr., Greer BE, Blessing JA, Dembo AJ. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med 1982; 307: 1416– 21. 22 Tucker MA, D'Angio GJ, Boice JD, Strong LC, Li FP, Stovall M, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317: 588– 93. 23 Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rorth M. Increased risk of myelodysplasia and leukemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991; 338: 359– 63. 24 Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 1682– 7. Citing Literature Volume72, Issue1215 December 1993Pages 3723-3726 ReferencesRelatedInformation
Referência(s)